Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial.

Kang DW, Fairey AS, Boulé NG, Field CJ, Courneya KS.

BMJ Open. 2019 Jul 4;9(7):e026438. doi: 10.1136/bmjopen-2018-026438.

2.

Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation.

Mitra AP, Fairey AS, Skinner EC, Boorjian SA, Frank I, Schoenberg MP, Bivalacqua TJ, Hyndman ME, Reese AC, Steinberg GD, Large MC, Hulsbergen-van de Kaa CA, Bruins HM, Daneshmand S.

Urol Oncol. 2019 Jan;37(1):48-56. doi: 10.1016/j.urolonc.2018.10.013. Epub 2018 Nov 13.

PMID:
30446450
3.

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH.

Can Urol Assoc J. 2018 Aug;12(8):231-238. doi: 10.5489/cuaj.5462. Epub 2018 May 31. No abstract available.

4.

Editorial Comment.

Wollin TA, Fairey AS.

J Urol. 2018 Nov;200(5):979-980. doi: 10.1016/j.juro.2018.04.103. Epub 2018 Jul 25. No abstract available.

PMID:
30053420
5.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
6.

Orthotopic bladder substitution for bladder cancer patients undergoing radical cystectomy: A call to action.

Fairey AS, Mclarty R.

Can Urol Assoc J. 2018 Jun;12(6):187. doi: 10.5489/cuaj.5427. No abstract available.

7.

Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors.

Adams SC, DeLorey DS, Davenport MH, Fairey AS, North S, Courneya KS.

Br J Cancer. 2018 May;118(10):1313-1321. doi: 10.1038/s41416-018-0044-7. Epub 2018 May 8.

8.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

9.

Taking it to the HILT: High-intensity local treatment with radical cystectomy for metastatic bladder cancer.

Fairey AS, Jacobsen NE.

Can Urol Assoc J. 2017 Aug;11(8):249-250. doi: 10.5489/cuaj.4800. No abstract available.

10.

Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial.

Adams SC, DeLorey DS, Davenport MH, Stickland MK, Fairey AS, North S, Szczotka A, Courneya KS.

Cancer. 2017 Oct 15;123(20):4057-4065. doi: 10.1002/cncr.30859. Epub 2017 Jul 14.

11.

Assessment of Wound Complications After Bulbar Urethroplasty: The Impact of a Lambda Perineal Incision.

Bascom A, Ghosh S, Fairey AS, Rourke KF.

Urology. 2016 Apr;90:184-8. doi: 10.1016/j.urology.2015.12.047. Epub 2016 Jan 8.

PMID:
26777749
12.

AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.

Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A.

Prostate. 2016 May;76(6):597-608. doi: 10.1002/pros.23151. Epub 2016 Jan 15.

PMID:
26771938
13.

Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer.

Skinner EC, Fairey AS, Groshen S, Daneshmand S, Cai J, Miranda G, Skinner DG.

J Urol. 2015 Aug;194(2):433-9. doi: 10.1016/j.juro.2015.03.101. Epub 2015 Mar 28.

PMID:
25823791
14.

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.

Eur Urol. 2015 Feb;67(2):241-9. doi: 10.1016/j.eururo.2014.09.007. Epub 2014 Sep 23.

15.

Conditional survival after radical nephroureterectomy for upper tract carcinoma.

Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, Shariat SF, Kassouf W.

Eur Urol. 2015 Apr;67(4):803-12. doi: 10.1016/j.eururo.2014.08.003. Epub 2014 Aug 19.

PMID:
25145551
16.

Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.

Fairey AS, Daneshmand S, Skinner EC, Schuckman A, Cai J, Lieskovsky G.

Urol Oncol. 2014 Feb;32(2):85-91. doi: 10.1016/j.urolonc.2013.03.005. Epub 2013 Oct 30.

PMID:
24183191
17.

Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.

Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W.

Eur Urol. 2014 Aug;66(2):361-70. doi: 10.1016/j.eururo.2013.09.050. Epub 2013 Oct 9.

PMID:
24139235
18.

Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.

Fairey AS, Jacobsen NE, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Kassouf W.

Eur Urol. 2013 Sep;64(3):518-9. doi: 10.1016/j.eururo.2013.06.014. Epub 2013 Jun 19. No abstract available.

PMID:
23796500
19.

Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.

Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H, Cai J, Miranda G, Skinner EC.

Urol Oncol. 2014 Feb;32(2):110-6. doi: 10.1016/j.urolonc.2012.04.020. Epub 2013 Mar 14.

PMID:
23499168
20.

Association between urinary diversion and quality of life after radical cystectomy.

Metcalfe M, Estey E, Jacobsen NE, Voaklander D, Fairey AS.

Can J Urol. 2013 Feb;20(1):6626-31.

PMID:
23433134
21.

Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration.

Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Jacobsen NE.

BJU Int. 2013 Oct;112(6):791-7. doi: 10.1111/j.1464-410X.2012.11474.x. Epub 2012 Nov 13.

22.

Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.

Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC.

Urol Oncol. 2013 Nov;31(8):1737-43. doi: 10.1016/j.urolonc.2012.07.005. Epub 2012 Nov 7.

PMID:
23141776
23.

Robotic intracorporeal orthotopic ileal neobladder: replicating open surgical principles.

Goh AC, Gill IS, Lee DJ, de Castro Abreu AL, Fairey AS, Leslie S, Berger AK, Daneshmand S, Sotelo R, Gill KS, Xie HW, Chu LY, Aron M, Desai MM.

Eur Urol. 2012 Nov;62(5):891-901. doi: 10.1016/j.eururo.2012.07.052. Epub 2012 Aug 17.

PMID:
22920581
24.

Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.

Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S.

Urol Oncol. 2013 Nov;31(8):1441-7. doi: 10.1016/j.urolonc.2012.03.006. Epub 2012 Apr 18.

PMID:
22516714
25.

Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database.

Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP.

Urol Oncol. 2012 Nov-Dec;30(6):825-32. doi: 10.1016/j.urolonc.2011.07.014. Epub 2011 Sep 1.

PMID:
21889368
26.

Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Chalasani V, Kassouf W, Chin JL, Fradet Y, Aprikian AG, Fairey AS, Estey E, Lacombe L, Rendon R, Bell D, Cagiannos I, Drachenberg D, Lattouf JB, Izawa JI.

Can Urol Assoc J. 2011 Apr;5(2):83-7. doi: 10.5489/cuaj.10040.

27.

Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.

Miles BJ, Fairey AS, Eliasziw M, Estey EP, Venner P, Finch D, Trpkov K, Eigl BJ.

Can Urol Assoc J. 2010 Aug;4(4):263-7.

28.

Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.

Fairey AS, Jacobsen NE, Chetner MP, Mador DR, Metcalfe JB, Moore RB, Rourke KF, Todd GT, Venner PM, Voaklander DC, Estey EP.

J Urol. 2009 Jul;182(1):85-92; discussion 93. doi: 10.1016/j.juro.2008.11.111. Epub 2009 May 17.

PMID:
19447413
29.

Exercise beliefs of breast cancer survivors before and after participation in a randomized controlled trial.

Courneya KS, Jones LW, Mackey JR, Fairey AS.

Int J Behav Med. 2006;13(3):259-64.

PMID:
17078777
30.

Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Martin BS, Mackey JR.

Brain Behav Immun. 2005 Sep;19(5):381-8.

PMID:
15922556
31.

A longitudinal study of exercise barriers in colorectal cancer survivors participating in a randomized controlled trial.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Vallance JK, Fairey AS.

Ann Behav Med. 2005 Apr;29(2):147-53.

PMID:
15823788
32.

Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors.

Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, Mackey JR.

J Appl Physiol (1985). 2005 Apr;98(4):1534-40.

35.

Predictors of adherence and contamination in a randomized trial of exercise in colorectal cancer survivors.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS.

Psychooncology. 2004 Dec;13(12):857-66.

PMID:
15386794
36.

A randomized trial of exercise and quality of life in colorectal cancer survivors.

Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS.

Eur J Cancer Care (Engl). 2003 Dec;12(4):347-57.

PMID:
14982314
38.

Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.

Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS.

J Clin Oncol. 2003 May 1;21(9):1660-8.

PMID:
12721239
39.

Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions.

Fairey AS, Courneya KS, Field CJ, Mackey JR.

Cancer. 2002 Jan 15;94(2):539-51. Review.

Supplemental Content

Loading ...
Support Center